Baxter Faces Class Action Lawsuit Over Device Defects
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Globenewswire
- Lawsuit Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Baxter International (BAX) in the Northern District of Illinois on behalf of investors who purchased shares between February 23, 2022, and October 29, 2025, indicating significant investor dissatisfaction with the company's transparency.
- Defect Allegations: The complaint alleges that Baxter failed to disclose systemic defects in its Novum LVP devices, leading to severe infusion issues that increased the risk of serious injury or death for patients, highlighting major failures in product safety management.
- Sales Impact: Due to these defects, Baxter faces the risk of customers being instructed to withdraw existing Novum LVPs from service and pausing all new sales, which could negatively impact the company's revenue and market reputation.
- Investor Rights: Investors must apply by December 15, 2025, to be appointed as lead plaintiffs in the lawsuit, reflecting concerns over corporate governance and investor rights protection, which may lead to increased regulatory scrutiny and legal liabilities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 21.73 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
Current: 19.730
Low
15.00
Averages
21.73
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baxter International to Host Q4 2025 Earnings Call on February 12, 2026
- Earnings Call Announcement: Baxter International will host a conference call on February 12, 2026, at 7:30 a.m. Central Time to discuss its Q4 2025 financial results, aiming to provide investors and analysts with insights into its financial performance and future outlook.
- Participation Details: Participants are required to pre-register via the provided link to receive call information, ensuring that investors can smoothly join and stay updated on the latest company developments.
- Webcast Availability: The conference call will also be webcast on Baxter's website, allowing investors who cannot join by phone to listen to the meeting live, thereby enhancing transparency and information dissemination.
- Company Overview: With nearly a century of experience in the medtech field, Baxter is committed to providing medical devices and advanced injectable technologies, supported by approximately 38,000 employees, highlighting the company's significant role and impact in global healthcare.
Continue Reading
Earnings Momentum Review: BAX and Others Rated D
- Earnings Momentum Ratings: As the earnings season kicks off, Baxter International (BAX) and others are rated D for earnings momentum, indicating significant pressure on profitability that may undermine investor confidence.
- Multiple Companies Rated: Companies like Biogen (BIIB), Natera (NTRA), and Revolution Medicines (RVMD) also received D ratings, suggesting a notable decline in earnings expectations that could lead to stock price volatility.
- Market Impact: These ratings reflect a broader weakening of earnings momentum in the healthcare sector, potentially affecting the performance of related healthcare ETFs (such as XLV, VHT), prompting investors to reassess risks.
- Industry Outlook: As the earnings season progresses, market attention on healthcare stocks, particularly those with weak earnings momentum, may trigger broader industry adjustments and shifts in investment strategies.
Continue Reading